Sit Investment Associates Inc. decreased its position in Astrazeneca Plc (NYSE:AZN – Free Report) by 5.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 224,675 shares of the company’s stock after selling 14,170 shares during the period. Astrazeneca comprises 0.8% of Sit Investment Associates Inc.’s portfolio, making the stock its 26th biggest position. Sit Investment Associates Inc.’s holdings in Astrazeneca were worth $39,430,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of the company. Bank of America Corp DE lifted its stake in Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after acquiring an additional 1,461,786 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Astrazeneca by 2.1% during the 4th quarter. Fisher Asset Management LLC now owns 21,601,433 shares of the company’s stock worth $3,791,051,000 after purchasing an additional 438,709 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Astrazeneca by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 20,157,744 shares of the company’s stock worth $3,537,684,000 after purchasing an additional 445,014 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Astrazeneca by 9.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock worth $521,517,000 after purchasing an additional 582,183 shares during the last quarter. Finally, Holocene Advisors LP increased its position in shares of Astrazeneca by 41.8% during the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock worth $470,232,000 after purchasing an additional 1,807,565 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.
Astrazeneca Stock Up 2.0%
AZN stock opened at $182.48 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $283.00 billion, a PE ratio of 27.40, a PEG ratio of 1.56 and a beta of 0.25. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The business’s 50 day simple moving average is $189.75 and its 200 day simple moving average is $185.85.
Wall Street Analyst Weigh In
Several research firms have weighed in on AZN. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Astrazeneca in a research report on Monday. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Tuesday. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Finally, DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $205.33.
Get Our Latest Stock Report on AZN
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Read More
- Five stocks we like better than Astrazeneca
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
